Advising AML patients to participate in clinical trials
Progession of AML treatment over the past decades
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML